Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Update

by · The Markets Daily

Atossa Therapeutics, Inc. (NASDAQ:ATOS – Get Free Report) was the target of a large drop in short interest in December. As of December 15th, there was short interest totalling 8,200,000 shares, a drop of 29.3% from the November 30th total of 11,600,000 shares. Based on an average daily volume of 705,500 shares, the short-interest ratio is currently 11.6 days.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on ATOS shares. Ascendiant Capital Markets lifted their price target on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. StockNews.com cut Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Atossa Therapeutics in a research report on Thursday, December 12th.

Check Out Our Latest Report on Atossa Therapeutics

Hedge Funds Weigh In On Atossa Therapeutics

Several large investors have recently made changes to their positions in the business. Bank of New York Mellon Corp increased its holdings in shares of Atossa Therapeutics by 3,160.5% in the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after buying an additional 399,041 shares in the last quarter. Rhumbline Advisers acquired a new position in shares of Atossa Therapeutics in the second quarter worth about $161,000. Renaissance Technologies LLC raised its holdings in shares of Atossa Therapeutics by 11.9% during the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock valued at $1,846,000 after acquiring an additional 164,540 shares during the period. XTX Topco Ltd purchased a new position in Atossa Therapeutics during the 2nd quarter worth approximately $29,000. Finally, SG Americas Securities LLC lifted its position in shares of Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after purchasing an additional 30,037 shares in the last quarter. Institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Stock Performance

Shares of ATOS stock opened at $0.98 on Friday. Atossa Therapeutics has a 1 year low of $0.77 and a 1 year high of $2.31. The business’s fifty day moving average is $1.27 and its 200-day moving average is $1.31. The stock has a market cap of $123.42 million, a PE ratio of -4.46 and a beta of 1.21.

Atossa Therapeutics Company Profile

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Featured Articles